Scribe Therapeutics launches CRISPR platforms for cholesterol control

Scribe Therapeutics has unveiled preclinical data on two advanced CRISPR platforms—ELXR and XE—that promise to revolutionize hypercholesterolemia treatment through unprecedented genomic precision. The ELXR platform incorporates an allosteric regulatory domain that mimics DNMT3A autoinhibition, functioning as a molecular lock that activates only upon encountering the correct specific key; in vivo designs achieved sustained PCSK9 suppression with improved transcriptional specificity and reduced off-target transcriptional effects by ten- to one-hundredfold. For genome editing, XE—derived from engineered CasX—delivered potent, saturating liver editing across multiple loci in non-human primates with no significant detectable off-target editing, even at super-saturating 10X EC90 doses in primary human hepatocytes. An AI-enabled model called DeepXE cuts guide selection burden by roughly 50% with under a 10% false-negative rate. These advances support clinical translation of the ELXR approach into STX-1150, Scribe's lead LDL-C program, which demonstrated in non-human primates durable LDL-C lowering sustained for nearly 18 months—a milestone that could substantially expand the therapeutic arsenal for patients at moderate-to-high cardiovascular risk.